Emmaus Sickle Cell NDA Facing FDA Concerns About Clinical Meaningfulness

PGLG's application only has one Phase III trial, and Emmaus is hoping statistical re-analyses can address FDA skepticism about clinical meaningfulness of the primary endpoint data.